Delpor, Inc

Delpor is a clinical stage medical technology company that develops new therapeutic products. Delpor’s technology enables the sustained release of drugs without decline for one year or longer. The technology is used to address two unmet needs: a) Allows patients to achieve complete medication adherence for one year after a single administration of the drug, and b) Enables the efficacy of drugs with short half-life. The technology has been validated clinically in multiple studies including a phase 2 study of DLP-114, a once-yearly risperidone product for schizophrenia maintenance. Safety, efficacy, and PK data were positive. Delpor has also gathered positive market research data from over 200 high prescribing physicians and several payers in the US and EU. Delpor is pursuing new therapeutic products in CNS/Psychiatric Conditions (including schizophrenia, Opioid Use Disorder, Spasticity, and Parkinson’s), Chronic Pain (including Fibromyalgia), Autoimmune Diseases (including MS, Crohn’s, RA, and Lupus), and other conditions.